<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02914522</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-418-3898</org_study_id>
    <secondary_id>2016-001392-78</secondary_id>
    <nct_id>NCT02914522</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis</brief_title>
  <acronym>SELECTION</acronym>
  <official_title>Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the efficacy of filgotinib in the&#xD;
      induction and maintenance treatment of moderately to severely active ulcerative colitis (UC)&#xD;
      in participants who are biologic-naive and biologic-experienced.&#xD;
&#xD;
      Participants who complete the study, or met protocol specified efficacy discontinuation&#xD;
      criteria will have the option to enter a separate, long-term extension (LTE) study (Gilead&#xD;
      Study GS-US-418-3899: NCT02914535).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 14, 2016</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Induction Study: Percentage of Participants Who Achieved Endoscopy/Bleeding/Stool Frequency (EBS) Remission at Week 10</measure>
    <time_frame>Week 10</time_frame>
    <description>EBS remission was defined as an endoscopic subscore of 0 or 1; rectal bleeding subscore of 0; and at least a 1-point decrease in stool frequency from baseline to achieve a subscore of 0 or 1. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration); rectal bleeding subscore range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes; stool frequency subscore range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal. Total score for EBS ranged from 0 to 9 (sum of all subscores), with higher scores indicating more severe disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maintenance Study: Percentage of Participants Who Achieved EBS Remission at Week 58</measure>
    <time_frame>Week 58</time_frame>
    <description>EBS remission was defined as an endoscopic subscore of 0 or 1; rectal bleeding subscore of 0; and at least a 1-point decrease in stool frequency from baseline to achieve a subscore of 0 or 1. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration); rectal bleeding subscore range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes; stool frequency subscore range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal. Total score for EBS ranged from 0 to 9 (sum of all subscores), with higher scores indicating more severe disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Induction Study: Percentage of Participants Who Achieved MCS Remission at Week 10</measure>
    <time_frame>Week 10</time_frame>
    <description>MCS remission was defined as having a MCS of 2 or less and no single subscore higher than 1. The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease [spontaneous bleeding, ulceration]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and physician's global assessment (PGA). The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Study: Percentage of Participants Who Achieved an Endoscopic Subscore of 0 at Week 10</measure>
    <time_frame>Week 10</time_frame>
    <description>Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Study: Percentage of Participants Who Achieved Geboes Histologic Remission at Week 10</measure>
    <time_frame>Week 10</time_frame>
    <description>Geboes histologic remission was assessed using the Geboes histologic scores for evaluation of disease severity in ulcerative colitis and classifies histologic changes. Remission was defined as having Grade 0 of &lt;= 0.3, Grade 1 of &lt;= 1.1, Grade 2A of &lt;= 2A.3, Grade 2B of 2B.0, Grade 3 of 3.0, Grade 4 of 4.0, and Grade 5 of 5.0. Possible scores are Grade 0: Architectural changes (0.0=No abnormality to 0.3=Severe diffuse or multifocal abnormalities); Grade 1: Chronic inflammatory infiltrate (1.0=No increase to 1.3=Marked increase); Grade 2A: Eosinophils in lamina propria (2A.0=No increase to 2A.3-=Marked increase; Grade 2B: Neutrophils in lamina propria (2B.0= No increase to 2B.3=Marked increase); Grade 3: Neutrophils in epithelium (3.0=None to 3.3=&gt;50% crypts involved); Grade 4: Crypt destruction (4.0=none to 4.3=Unequivocal crypt destruction), and Grade 5: Erosions and ulcerations: (5.0=No erosion, ulceration or granulation to 5.4=Ulcer or granulation tissue).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Study: Percentage of Participants Who Achieved MCS Remission (Alternative Definition) at Week 10</measure>
    <time_frame>Week 10</time_frame>
    <description>MCS remission (alternative definition) was defined as having rectal bleeding, stool frequency, and PGA subscores of 0 and an endoscopic subscore of 0 or 1; overall MCS of ≤ 1. MCS possible subscores: rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), PGA subscore (range: 0 to 3 with higher score indicating the severe disease), and an endoscopic subscore (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease [spontaneous bleeding, ulceration]. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Study: Pharmacokinetic (PK) Parameter: Cmax of Filgotinib and Its Metabolite GS-829845</measure>
    <time_frame>Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10</time_frame>
    <description>Cmax is defined as the maximum observed concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Study: PK Parameter: Tmax of Filgotinib and Its Metabolite GS-829845</measure>
    <time_frame>Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10</time_frame>
    <description>Tmax is defined as the time to reach maximum observed concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Study: PK Parameter: AUCtau of Filgotinib and Its Metabolite GS-82984</measure>
    <time_frame>Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10</time_frame>
    <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Study: PK Parameter: AUClast of Filgotinib and Its Metabolite GS-82984</measure>
    <time_frame>Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10</time_frame>
    <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction Study: PK Parameter: Ctau of Filgotinib and Its Metabolite GS-82984</measure>
    <time_frame>Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10</time_frame>
    <description>Ctau is defined as the observed drug concentration at the end of the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Study: Percentage of Participants Who Achieved MCS Remission at Week 58</measure>
    <time_frame>Week 58</time_frame>
    <description>MCS remission was defined as having a MCS of 2 or less and no single subscore higher than 1. The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease [spontaneous bleeding, ulceration]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and PGA. The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Study: Percentage of Participants Who Achieved Sustained EBS Remission at Week 58</measure>
    <time_frame>Week 58</time_frame>
    <description>Sustained EBS remission was defined as having achieved EBS remission at both Weeks 10 and 58.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Study: Percentage of Participants Who Achieved 6-Month Corticosteroid-Free EBS Remission at Week 58</measure>
    <time_frame>Week 58</time_frame>
    <description>Six-month corticosteroid-free EBS remission at Week 58 was defined as achieving EBS remission with no corticosteroid use for the indication of ulcerative colitis for at least 6 months prior to Week 58.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Study: Percentage of Participants Who Achieved Endoscopic Subscore of 0 at Weeks 58</measure>
    <time_frame>Week 58</time_frame>
    <description>Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Study: Percentage of Participants Who Achieved Geboes Histologic Remission at Week 58</measure>
    <time_frame>Week 58</time_frame>
    <description>Geboes histologic remission was assessed using the Geboes histologic scores for evaluation of disease severity in ulcerative colitis and classifies histologic changes. Remission was defined as having Grade 0 of &lt;= 0.3, Grade 1 of &lt;= 1.1, Grade 2A of &lt;= 2A.3, Grade 2B of 2B.0, Grade 3 of 3.0, Grade 4 of 4.0, and Grade 5 of 5.0. Possible scores are Grade 0: Architectural changes (0.0=No abnormality to 0.3=Severe diffuse or multifocal abnormalities); Grade 1: Chronic inflammatory infiltrate (1.0=No increase to 1.3=Marked increase); Grade 2A: Eosinophils in lamina propria (2A.0=No increase to 2A.3-=Marked increase; Grade 2B: Neutrophils in lamina propria (2B.0= No increase to 2B.3=Marked increase); Grade 3: Neutrophils in epithelium (3.0=None to 3.3=&gt;50% crypts involved); Grade 4: Crypt destruction (4.0=none to 4.3=Unequivocal crypt destruction), and Grade 5: Erosions and ulcerations: (5.0=No erosion, ulceration or granulation to 5.4=Ulcer or granulation tissue).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Study: Percentage of Participants Who Achieved MCS Remission (Alternative Definition) at Week 58</measure>
    <time_frame>Week 58</time_frame>
    <description>MCS remission (alternative definition) was defined as having rectal bleeding, stool frequency, and PGA subscores of 0 and an endoscopic subscore of 0 or 1; overall MCS of ≤ 1. MCS possible subscores: rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), PGA subscore (range: 0 to 3 with higher score indicating the severe disease), and an endoscopic subscore (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease [spontaneous bleeding, ulceration]. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Study: Plasma Concentration of Filgotinib and Its Metabolite GS-829845</measure>
    <time_frame>Week 26 (any Time) and Week 58 (predose)</time_frame>
    <description>Plasma concentration is defined as the measured drug concentration of filgotinib and its metabolite GS-829845. Lower limit of quantitation (LLOQ) was defined as 1 ng/mL for analyte filgotinib and 2 ng/mL for analyte GS-829845.</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">1351</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Induction Study (Cohort A): Filgotinib 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Cohort A (biologic-naive) received filgotinib 200 milligrams (mg) and placebo-to-match (PTM) filgotinib 100 mg orally once daily for 10 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction Study (Cohort A): Filgotinib 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Cohort A (biologic-naive) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction Study (Cohort A): Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in Cohort A (biologic-naive) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction Study (Cohort B): Filgotinib 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Cohort B (biologic-experienced) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction Study (Cohort B): Filgotinib 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Cohort B (biologic-experienced) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction Study (Cohort B): Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in Cohort B (biologic-experienced) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either Endoscopy/Bleeding/Stool Frequency (EBS) remission or Mayo Clinic Score (MCS) response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 200 mg and PTM filgotinib 100 mg for an additional 47 weeks (up to Week 58).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance Study: Placebo From Induction Filgotinib 200 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 100 mg and PTM filgotinib 200 mg for an additional 47 weeks (up to Week 58).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance Study: Placebo From Induction Filgotinib 100 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were rerandomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance Study: Placebo From Induction Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in the Placebo arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib for an additional 47 weeks (up to Week 58).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgotinib</intervention_name>
    <description>Tablet(s) administered orally once daily</description>
    <arm_group_label>Induction Study (Cohort A): Filgotinib 100 mg</arm_group_label>
    <arm_group_label>Induction Study (Cohort A): Filgotinib 200 mg</arm_group_label>
    <arm_group_label>Induction Study (Cohort B): Filgotinib 100 mg</arm_group_label>
    <arm_group_label>Induction Study (Cohort B): Filgotinib 200 mg</arm_group_label>
    <arm_group_label>Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg</arm_group_label>
    <arm_group_label>Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg</arm_group_label>
    <other_name>GS-6034</other_name>
    <other_name>GLPG0634</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTM filgotinib</intervention_name>
    <description>Tablet(s) administered orally once daily</description>
    <arm_group_label>Induction Study (Cohort A): Filgotinib 100 mg</arm_group_label>
    <arm_group_label>Induction Study (Cohort A): Filgotinib 200 mg</arm_group_label>
    <arm_group_label>Induction Study (Cohort A): Placebo</arm_group_label>
    <arm_group_label>Induction Study (Cohort B): Filgotinib 100 mg</arm_group_label>
    <arm_group_label>Induction Study (Cohort B): Filgotinib 200 mg</arm_group_label>
    <arm_group_label>Induction Study (Cohort B): Placebo</arm_group_label>
    <arm_group_label>Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg</arm_group_label>
    <arm_group_label>Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg</arm_group_label>
    <arm_group_label>Maintenance Study: Placebo From Induction Filgotinib 100 mg</arm_group_label>
    <arm_group_label>Maintenance Study: Placebo From Induction Filgotinib 200 mg</arm_group_label>
    <arm_group_label>Maintenance Study: Placebo From Induction Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Males or non-pregnant, non-lactating females, ages 18 to 75 years, inclusive based on&#xD;
             the date of the screening visit&#xD;
&#xD;
          -  Documented diagnosis of UC of at least 6 months AND with a minimum disease extent of&#xD;
             15 cm from the anal verge. Documentation should include endoscopic and histopathologic&#xD;
             evidence of UC.&#xD;
&#xD;
          -  A surveillance colonoscopy is required at screening in individuals with a history of&#xD;
             UC for 8 or more years, if one was not performed in the prior 24 months&#xD;
&#xD;
          -  Moderately to severely active UC&#xD;
&#xD;
          -  Previously demonstrated an inadequate clinical response, loss of response to, or&#xD;
             intolerance to at least 1 of the following agents (depending on current country&#xD;
             treatment recommendations/guidelines): corticosteroids, immunomodulators, tumor&#xD;
             necrosis factor alpha (TNFa) antagonists, or vedolizumab&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Presence of Crohn's disease, indeterminate colitis, ischemic colitis, fulminant&#xD;
             colitis, ulcerative proctitis, or toxic mega-colon&#xD;
&#xD;
          -  Active tuberculosis (TB) or history of latent TB that has not been treated&#xD;
&#xD;
          -  Use of any concomitant prohibited medications as described in the protocol&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Digestive Health Specialists of the Southeast</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Denver Gastroenterology, PC</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut GI PC-Research Division</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Health at Shands Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Research Institute</name>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Crohn's and Colitis Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cordova Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Group of Naples</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research Center</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shafran Gastroenterology Center</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Medical Clinic, P.A.</name>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <zip>33540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Central Georgia, LLC</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Specialists of Georgia</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Gastroenterology Specialist, PC</name>
      <address>
        <city>Suwanee</city>
        <state>Georgia</state>
        <zip>30024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville, Clinical Trials Unit</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delta Research Partners, LLC</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana Research Center, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Clinical Research</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MGG Group Co., Inc., Chevy Chase Clinical Research</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro Center of Maryland</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meritus Center for Clinical Research</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital - Crohn's and Colitis Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Michigan, LLC</name>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <zip>48047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Digestive Health</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Scientific</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Long Island Clinical Research Associates</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina's GI Research, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fargo Gastroenterology and Hepatology Clinic</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants for Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Health Physicians Clifton</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Gastroenterology Research, LLC</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Orangeburg</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid City Medical Center</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WR-ClinSearch, LLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro One</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Medical Research</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center - IBD Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212-1375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Military Medical Center</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DHAT Research Institute</name>
      <address>
        <city>Garland</city>
        <state>Texas</state>
        <zip>75044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine- Baylor Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Associates in Research Therapeutics of America, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Research of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consultants</name>
      <address>
        <city>San Marcos</city>
        <state>Texas</state>
        <zip>78666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consultants</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spring Gastroenterology</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HP Clinical Research</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates Of Tidewater</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emeritas Research Group LLC</name>
      <address>
        <city>Lansdowne Town Center</city>
        <state>Virginia</state>
        <zip>20176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGuire DVAMC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital &amp; Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegiance Research Specialists, LLC</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Clinicas Mar del Plata</name>
      <address>
        <city>Mar del Plata</city>
        <zip>B7600FZN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Médico Cer</name>
      <address>
        <city>Quilmes</city>
        <zip>B1878</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Digestive Health</name>
      <address>
        <city>Mountain Creek</city>
        <state>Queensland</state>
        <zip>4557</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae Ltd</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Footscray Hospital</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabrini Hospital</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH-Medizinische Universitat Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GZA Ziekenhuizen campus Sint-Vincentius</name>
      <address>
        <city>Antwerpen</city>
        <zip>2018</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CUB Hopital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Chretien (CHC) - Clinique Saint-Joseph</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Sveti Pantaleymon - Pleven OOD</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;MDHAT Dr. St.Cherkezov&quot; AD</name>
      <address>
        <city>Veliko Tŭrnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Sveta Petka&quot; AD</name>
      <address>
        <city>Vidin</city>
        <zip>3700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary, Heritage Medical Research Clinic</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Gordon and Leslie Diamond Health Care Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Corporation, McMaster University Medical Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 4K1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Digestive Disease Associates Inc.</name>
      <address>
        <city>Vaughan</city>
        <zip>L4L 4Y7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Dubrava</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Center Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepato-Gastroenterologie HK, s.r.o.</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 12</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oblastni nemocnice Mlada Boleslav, a.s., nemocnice Stredoceskeho kraje, Gastroenterologicke oddeleni</name>
      <address>
        <city>Mladá Boleslav</city>
        <zip>293 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G.E.P. Clinic, s r.o.</name>
      <address>
        <city>Praha 3</city>
        <zip>130 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ISCARE a.s. (Klinicke centrum ISCARE), Klinicke a vyzkumne centrum pro strevni zanety</name>
      <address>
        <city>Praha 9</city>
        <zip>190 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand - Hopital d'Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hopital Beaujon - Clichy - Universite Paris VII</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon Bourgogne - Hopital Francois Mitterand</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble Alpes</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire de Bicetre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier-Hopital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hotel-Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de l'Archet 2</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hopital Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Lyon Sud</name>
      <address>
        <city>Pierre-Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou</name>
      <address>
        <city>Rennes Cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne - Hopital Nord</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hopital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy - Hopital Brabois Adultes</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unimed Ajara LLC - Batumi Referral Hospital</name>
      <address>
        <city>Batumi</city>
        <zip>6010</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medi Club Georgia LLC</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ltd. Unimed Kakheti - Telavi Referral Hospital</name>
      <address>
        <city>Telavi</city>
        <zip>2200</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitatsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Universitatsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRK Kliniken Berlin - Westend - Klinik fuer Innere Medizin</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stadtisches Klinikum Braunschweig gGmbH</name>
      <address>
        <city>Braunschweig</city>
        <zip>38126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agaplesion Markus Krankenhaus</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Westklinikum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannöver</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologische Gemeinschaftspraxis Herne</name>
      <address>
        <city>Herne</city>
        <zip>44623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Koln</name>
      <address>
        <city>Koln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EUGASTRO GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Luneburg</name>
      <address>
        <city>Lüneburg</city>
        <zip>21339</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologische Gemeinschaftspraxis Minden</name>
      <address>
        <city>Minden</city>
        <zip>32423</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitat Munchen - Grosshadern</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Ulm, Zentrum Fur Innere Medizin</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Hippokratio&quot;, 2nd Internal Medicine Clinic of Athens University, Hepato-gastroenterology Unit</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Nikaias &quot;Agios Pentelleimon&quot;, Gastroenterology Department</name>
      <address>
        <city>Athens</city>
        <zip>18454</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine &amp; Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital</name>
      <address>
        <city>Sha Tin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet, Kozponti Felnott Szakrendelo</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Janos Korhaz es Eszak-budai Egitett Korhazak, I. Belgyogyaszati - Gasztroenterologiai Osztaly</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Kosponti Korhaz, Dr. Rethy Pal Tagkorhaz, IV. Belgyogyaszat - 2. Gasztroenterologia</name>
      <address>
        <city>Békéscsaba</city>
        <zip>5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont, II. sz. Belgyogyaszati Klinika, Gasztroenterologia</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bugat Pal Korhaz, Belgyogyaszat</name>
      <address>
        <city>Gyöngyös</city>
        <zip>3200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolina Korhaz es Rendelointezet, Altalanos Belgyogyaszat-Gasztroenterologia</name>
      <address>
        <city>Mosonmagyaróvár</city>
        <zip>9200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaizen Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380052</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M S Ramaiah Medical College and Hospital</name>
      <address>
        <city>Bangalore</city>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Speciality Hospital</name>
      <address>
        <city>Chennai</city>
        <zip>600035</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VGM Hospital Institute of Gastroenterology</name>
      <address>
        <city>Coimbatore</city>
        <zip>641005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gleneagles Global Hospitals</name>
      <address>
        <city>Hyderabad</city>
        <zip>500004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Citizens Specialty Hospital</name>
      <address>
        <city>Hyderabad</city>
        <zip>500019</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Liver Research &amp; Diagnostics</name>
      <address>
        <city>Hyderabad</city>
        <zip>500058</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.R.KallaMemorial Gastro.&amp;General Hospital,</name>
      <address>
        <city>Jaipur</city>
        <zip>302001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.M.S Medical College &amp; Hospitals</name>
      <address>
        <city>Jaipur</city>
        <zip>302004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>School of Digestive &amp; Liver Diseases</name>
      <address>
        <city>Kolkata</city>
        <zip>700020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayanand Medical College &amp; Hospital</name>
      <address>
        <city>Ludhiana</city>
        <zip>141001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasturba Medical College (KMC) Hospital</name>
      <address>
        <city>Mangaluru</city>
        <zip>575001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lokmanya Tilak Municipal General Hospital</name>
      <address>
        <city>Mumbai</city>
        <zip>400022</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midas Multispeciality Hospital Pvt. Ltd</name>
      <address>
        <city>Nagpur</city>
        <zip>400010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suretech Hospital &amp; Research Centre Ltd</name>
      <address>
        <city>Nagpur</city>
        <zip>440012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grant Medical Foundation Ruby Hall Clinic</name>
      <address>
        <city>Pune</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shree Giriraj Multispeciality Hospital</name>
      <address>
        <city>Rajkot</city>
        <zip>360005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gandhi Hospital</name>
      <address>
        <city>Secunderabad</city>
        <zip>500003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Gastroenterology &amp; Liver Disease, Sunshine Hospitals</name>
      <address>
        <city>Secunderabad</city>
        <zip>500003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surat Institute of Digestive Sciences</name>
      <address>
        <city>Surat</city>
        <zip>395002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasturba Hospital Medical College</name>
      <address>
        <city>Udupi</city>
        <zip>576104</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Hospital</name>
      <address>
        <city>Vadodara</city>
        <zip>390007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samvedana Hospital</name>
      <address>
        <city>Varanasi</city>
        <zip>221005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>9</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Beer-Sheva</city>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Gastroenterologia II</name>
      <address>
        <city>Castellana Grotte</city>
        <zip>Bari 70013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Fisiopatologia Digestiva</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Clinicizzato SS. Annunziata - Dipartimento di Medicina</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocsopia Digestiva Centralizzata - ASST Fatebenefratelli Sacco, Ospedale Fatebenefratelli e Oftalmico</name>
      <address>
        <city>Milano</city>
        <zip>20121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Gastroenterologia</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Pisana - Presidio Ospedaliero Cisanello</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Gastroenterologia ed Endoscopia Digestiva</name>
      <address>
        <city>Roma</city>
        <zip>128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Hospital, Tokyo Medical and Dental University</name>
      <address>
        <city>Bunkyo-ku</city>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka University Chikushi Hospital</name>
      <address>
        <city>Chikushino-shi</city>
        <zip>818-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido P.W.F.A.C Sapporo-Kosei General Hospital</name>
      <address>
        <city>Chuo-Ku</city>
        <zip>060-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Fukuoka Hospital</name>
      <address>
        <city>Fukuoka-shi</city>
        <zip>815-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai University Hachioji Hospital</name>
      <address>
        <city>Hachioji-shi</city>
        <zip>192-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima-shi</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka University Hospital</name>
      <address>
        <city>Jonan-ku</city>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ofuna Chuo Hospital</name>
      <address>
        <city>Kamakura</city>
        <zip>247-0056</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitakyushu City Hospital Organization Kitakyushu Municipal Medical Center</name>
      <address>
        <city>Kitakyushu-shi</city>
        <zip>802-0077</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamanashi Prefectural Central Hospital</name>
      <address>
        <city>Kofu-shi</city>
        <zip>400-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Kurume-shi</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hidaka Coloproctology Clinic</name>
      <address>
        <city>Kurume-shi</city>
        <zip>839-0809</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Kyoto Prefectural University of Medicine</name>
      <address>
        <city>Kyoto-shi</city>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jikei University Hospital</name>
      <address>
        <city>Minato-Ku</city>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitasato University Kitasato Institute Hospital</name>
      <address>
        <city>Minato-ku</city>
        <zip>108-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyorin University Hospital</name>
      <address>
        <city>Mitaka-shi</city>
        <zip>181-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University Hospital</name>
      <address>
        <city>Morioka-shi</city>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Medical University Hospital</name>
      <address>
        <city>Nagakute-shi</city>
        <zip>480-1195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital</name>
      <address>
        <city>Nagasaki-shi</city>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Niigata Daini Hospital</name>
      <address>
        <city>Nishi-ku</city>
        <zip>950-1104</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine College Hospital</name>
      <address>
        <city>Nishinomiya</city>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ishida IBD Clinic</name>
      <address>
        <city>Oita-shi</city>
        <zip>870-0823</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama-city</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wakakusa-Daiichi Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>579-8056</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saga-Ken Medical Centre Koseikan</name>
      <address>
        <city>Saga-shi</city>
        <zip>840-8571</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitasato University Hospital, THE KITASATO INSTITUTE</name>
      <address>
        <city>Sagamihara</city>
        <zip>252-0375</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saga University Hospital</name>
      <address>
        <city>Saga</city>
        <zip>849-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokito Clinic</name>
      <address>
        <city>Saitama</city>
        <zip>336-0963</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University Sakura Medical Center</name>
      <address>
        <city>Sakura</city>
        <zip>285-8741</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Higashi Tokushukai Hospital</name>
      <address>
        <city>Sapporo-shi</city>
        <zip>065-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Tokushukai Hospital</name>
      <address>
        <city>Sapporo</city>
        <zip>004-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Sendai Medical Center</name>
      <address>
        <city>Sendai</city>
        <zip>983-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Yamate Medical Center</name>
      <address>
        <city>Shinjuku-ku</city>
        <zip>169-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagawa Prefectural Central Hospital</name>
      <address>
        <city>Takamatsu-shi</city>
        <zip>760-8557</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Takasaki General Medical Center</name>
      <address>
        <city>Takasaki-shi</city>
        <zip>3700829</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Medical College Hospital</name>
      <address>
        <city>Takatsuki</city>
        <zip>569-8686</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ieda Hospital</name>
      <address>
        <city>Toyota-shi</city>
        <zip>470-1219</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical University Hospital</name>
      <address>
        <city>Wakayama-shi</city>
        <zip>641-8509</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colo-proctology Center Matsushima Clinic</name>
      <address>
        <city>Yokohama-shi</city>
        <zip>220-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Health Medicine Association Kannai Suzuki Clinic</name>
      <address>
        <city>Yokohama-shi</city>
        <zip>231-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinshukai Infusion Clinic</name>
      <address>
        <city>Ōsaka</city>
        <zip>530-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Ōsaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shiga University of Medical Science Hospital</name>
      <address>
        <city>Ōtsu</city>
        <zip>520-2912</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, St. Vincent's Hospital</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-do</state>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>609801</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03181</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Gastroenterology, Department of Medicine, Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>130-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Wonju Severance Christian Hospital</name>
      <address>
        <city>Wŏnju</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Kebangsaan Malaysia Medical Centre</name>
      <address>
        <city>Cheras</city>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pulau Pinang</name>
      <address>
        <city>George Town</city>
        <zip>10990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Queen Elizabeth</name>
      <address>
        <city>Kota Kinabalu</city>
        <zip>88586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PCR-Phylasis Clinicas Research S. de R.L. de C.V.</name>
      <address>
        <city>Cuautitlán Izcalli</city>
        <zip>54750</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <zip>1100</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gelre Hospital</name>
      <address>
        <city>Apeldoorn</city>
        <zip>7334</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Grafton</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>3240</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellington Hospital</name>
      <address>
        <city>Newtown</city>
        <zip>WE 6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay of Plenty District Health Board - Tauranga Hospital</name>
      <address>
        <city>Tauranga</city>
        <zip>3134</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vestre Viken Hospital Trust, Baerum Hospital</name>
      <address>
        <city>Drammen</city>
        <zip>1346</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akerskus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <zip>N-1478</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny w Bialymstoku, Klinika Gastroenterologii i Chorob Wewnetrznych</name>
      <address>
        <city>Białystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VITAMED Galaj i Cichomski spolka jawna</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-079</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Lekarski Janusz Rudzinski</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-681</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ INTER-MED, Centrum Endoskopowe</name>
      <address>
        <city>Częstochowa</city>
        <zip>42-217</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej ALL-MEDICUS</name>
      <address>
        <city>Katowice</city>
        <zip>40-659</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Endoskopii Przewodu Pokarmowego</name>
      <address>
        <city>Kraków</city>
        <zip>31-009</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowskie Centrum Medyczne Sp. z o.o</name>
      <address>
        <city>Kraków</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Opieki Zdrowotnej Orkan-Med Stec-Michalska Sp.J.</name>
      <address>
        <city>Ksawerów</city>
        <zip>95-054</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Innowacyjnych Terapii Sp. z o.o.</name>
      <address>
        <city>Piaseczno</city>
        <zip>05-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center Spolka z organiczna odpowiedzialnoscia Medic-R Sp. k.</name>
      <address>
        <city>Poznan</city>
        <zip>60-848</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Lekarski Dr. Hab. N. Med. Bartosz Korczowski</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-301</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endoskopia Sp. z o.o.</name>
      <address>
        <city>Sopot</city>
        <zip>81-756</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Twoja Przychodnia-Szczecinskie Centrum Medyczne</name>
      <address>
        <city>Szczecin</city>
        <zip>71-434</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GASTROMED Kopon, Zmudzkinski i Wspolnicy Sp. j. Specjalistyczne Centrum Gastrologii i Endoskopii</name>
      <address>
        <city>Toruń</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H-T.Centrum Medyczne Spolka z Ograniczona Odpowiedzialnoscia Sp.K.</name>
      <address>
        <city>Tychy</city>
        <zip>43-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Zdrowia MDM</name>
      <address>
        <city>Warszawa</city>
        <zip>0-635</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bodyclinic</name>
      <address>
        <city>Warszawa</city>
        <zip>00-332</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administacji w Warszawie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zrodotnej VIVAMED Jadwige Miecz</name>
      <address>
        <city>Warszawa</city>
        <zip>03-580</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Oporow</name>
      <address>
        <city>Wroclaw</city>
        <zip>52-416</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Familia, Centrum Badan, Profilaktyki i Leczenia</name>
      <address>
        <city>Łódź</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital da Senhora da Oliveira Guimaraes, E.P.E.</name>
      <address>
        <city>Guimarães</city>
        <zip>4835-044</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Sao Joao, EPE</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC MedLife SA, Gastroenterologie</name>
      <address>
        <city>Bucuresti</city>
        <zip>010719</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Colentina - Sectia de Spitulal Clinic Colentina, Gastroenterologie</name>
      <address>
        <city>Bucuresti</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Medical Individual Dr Tirnaveanue Amelita, Gastroenterologie</name>
      <address>
        <city>Oradea</city>
        <zip>410066</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Particular Policlinic Algomed SRL</name>
      <address>
        <city>Timişoara</city>
        <zip>300002</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution &quot;Chelyabinski Regional Clinical Hospital&quot;</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Health Irkustsk Order &quot;Badge of Honor&quot; Regional Clinical Hospital</name>
      <address>
        <city>Irkutsk</city>
        <zip>669079</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution of Science Federal Research Center of Nutrition, Biotechnology and Food Safety</name>
      <address>
        <city>Moscow</city>
        <zip>115446</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution of Moscow &quot;City Clinical Hospital # 24 of Healthcare Department of Moscow&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>127015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution of Moscow Region &quot;Moscow Regional Clinical Research Institute n.a. M.F. Vladimirskiy&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution of Nizhny Novgorod Region &quot;Nizhny Novgorod Regional Clinical Hospital n.a. N.A.</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Health of Novosibirsk Region &quot;City Clinical Hospital #12&quot;</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution of the Novosibirsk Region &quot;State Novosibirsk Regional Clinical Hospital&quot;</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Riat&quot; LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>193163</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;PolyClinic EXPERT&quot; LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Budgetary Healthcare Institution &quot;City Polyclinic #38&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Scientific Research Centre ECO-safety&quot; LLC</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>196143</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution &quot;Regional Clinical Hospital&quot;</name>
      <address>
        <city>Saratov</city>
        <zip>410053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Treatment and Prevention Interdistrict Institution &quot;Smolenskie kliniki&quot; LLC</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Autonomous Health Institution of the Tyumen Region &quot;Multidisciplinary Consultative and Diagnostic Center&quot;</name>
      <address>
        <city>Tyumen</city>
        <zip>625026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zvezdara University Medical Center</name>
      <address>
        <city>Belgrade</city>
        <zip>3810-971</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KM Management, s.r.o., Gastroenterologicke a hepatologicke centrum Nitra</name>
      <address>
        <city>Nitra</city>
        <zip>950 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr MJ Prins</name>
      <address>
        <city>Cape Town</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peermed Clinical Trial Centre</name>
      <address>
        <city>Johannesburg</city>
        <zip>1619</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Teknon</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Madrid</city>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danderyds Sjukhus AB</name>
      <address>
        <city>Danderyd</city>
        <zip>SE-18288</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Malmo</city>
        <zip>SE-205-02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologische Praxis Balsiger, Seibold und Partner</name>
      <address>
        <city>Bern</city>
        <zip>3012</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsspital Zurich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Chang-hua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital, Taipei</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation, Chang Gung Memorial Hospital, Linkou Branch</name>
      <address>
        <city>Taoyuan</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution &quot;Cherkasy Regional Hospital of Cherkasy Regional Council&quot;, Gastroenterology Department</name>
      <address>
        <city>Cherkasy</city>
        <zip>18000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal City Clinical Hospital of the Emergency Medical Care, 1 st Therapy Department. Danylo Halytsky Lviv National Medical</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Municipal Institution &quot;Chernivtsi Regional Clinical Hospital&quot;, Surgical Department</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution &quot;Institute of Gastroenterology of National Academy of Medical Sciences of Ukraine&quot;</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivanto-Frankivsk Central City Clinic Hospital, Therapy Department #1. State Higher Education Institution Ivano-Frankivsk National</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <zip>76000-490</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Health Care Institution &quot;Kharkiv City Clinical Hospital #2 named after prof. O. O. Shalimov&quot;, Proctology Department</name>
      <address>
        <city>Kharkiv</city>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L.T. Mala State Institution &quot;National Institute of Therapy of National Academy of Medical Sciences of Ukraine&quot;</name>
      <address>
        <city>Kharkiv</city>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution of Health Care &quot;Regional Hospital of War Veterans&quot;, Therapeutic Department No1</name>
      <address>
        <city>Kharkiv</city>
        <zip>63101</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Treatment and Diagnostic Center of Private Enterprise of Private Production Company &quot;Acinus&quot;</name>
      <address>
        <city>Kropyvnytskyi</city>
        <zip>25006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Hospital No. 18, Proctology Department</name>
      <address>
        <city>Kyiv</city>
        <zip>01030</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise &quot;Consultative and Diagnostic Center&quot; of Pechersk District of Kyiv, Therapy Department</name>
      <address>
        <city>Kyiv</city>
        <zip>1103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odesa Clinical Railway Hospital Branch of &quot;Healthcare Center&quot; of Public joint stock company &quot;Ukrainian Railway&quot;</name>
      <address>
        <city>Odessa</city>
        <zip>65010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution &quot;Odesa Regional Clinical Hospital&quot;, Regional Gastroenterology Center based on Surgery Department</name>
      <address>
        <city>Odessa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ternopil University Hospital, Regional Center of Gastroenterology with Hepatology</name>
      <address>
        <city>Ternopil</city>
        <zip>46002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center LLC &quot;Health Clinic&quot;</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytsia Regional Clinical Hospital of War Veterans, Therapy Department #1</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.I. Pyrogov Vinnytsia Regional Clinical Hospital, Gastroenterology Department</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution &quot;Zaporizhzhya Regional Clinical Hospital&quot; of Zaporizhzhya Regional Council</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Pennine Acute Hospitals NHS Trust</name>
      <address>
        <city>Bury</city>
        <zip>BL9 7TD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospital NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Derby Hospital</name>
      <address>
        <city>Derby</city>
        <zip>DE22 3NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Lothian</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glasgow Clinical Research Facility - Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde</name>
      <address>
        <city>Glasgow</city>
        <zip>G52 3NQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wycombe Hospital</name>
      <address>
        <city>High Wycombe</city>
        <zip>HP11 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust, St Mary's Hospital</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital NHS Foundation Trust</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biomedical Research Unit</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Helens and Knowsley Teaching Hospitals NHS Trust</name>
      <address>
        <city>Prescot</city>
        <zip>L35 5DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton National Institute for Health Research, Wellcome Trust Clinical Research Facility</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Iceland</country>
  </removed_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 22, 2016</study_first_submitted>
  <study_first_submitted_qc>September 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2016</study_first_posted>
  <results_first_submitted>March 23, 2021</results_first_submitted>
  <results_first_submitted_qc>March 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 21, 2021</results_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT02914522/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 28, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT02914522/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at study sites in Australia, New Zealand, North America, South America, Asia and Europe. The first participant was screened on 14 November 2016. The last study visit occurred on 31 March 2020.</recruitment_details>
      <pre_assignment_details>2040 participants were screened.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Induction Study (Cohort A): Filgotinib 200 mg</title>
          <description>Participants in Cohort A (biologic-naive) received filgotinib 200 milligrams (mg) and placebo-to-match (PTM) filgotinib 100 mg orally once daily for 10 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Induction Study (Cohort A): Filgotinib 100 mg</title>
          <description>Participants in Cohort A (biologic-naive) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Induction Study (Cohort A): Placebo</title>
          <description>Participants in Cohort A (biologic-naive) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Induction Study (Cohort B): Filgotinib 200 mg</title>
          <description>Participants in Cohort B (biologic-experienced) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Induction Study (Cohort B): Filgotinib 100 mg</title>
          <description>Participants in Cohort B (biologic-experienced) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Induction Study (Cohort B): Placebo</title>
          <description>Participants in Cohort B (biologic-experienced) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg</title>
          <description>Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either Endoscopy/Bleeding/Stool Frequency (EBS) remission or Mayo Clinic Score (MCS) response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for an additional 47 weeks (up to Week 58).</description>
        </group>
        <group group_id="P8">
          <title>Maintenance Study: Placebo From Induction Filgotinib 200 mg</title>
          <description>Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).</description>
        </group>
        <group group_id="P9">
          <title>Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg</title>
          <description>Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for an additional 47 weeks (up to Week 58).</description>
        </group>
        <group group_id="P10">
          <title>Maintenance Study: Placebo From Induction Filgotinib 100 mg</title>
          <description>Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were rerandomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).</description>
        </group>
        <group group_id="P11">
          <title>Maintenance Study: Placebo From Induction Placebo</title>
          <description>Participants in the Placebo arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction Study: Up to Week 11</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="245"/>
                <participants group_id="P2" count="278"/>
                <participants group_id="P3" count="137"/>
                <participants group_id="P4" count="262"/>
                <participants group_id="P5" count="286"/>
                <participants group_id="P6" count="143"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="235"/>
                <participants group_id="P2" count="256"/>
                <participants group_id="P3" count="127"/>
                <participants group_id="P4" count="234"/>
                <participants group_id="P5" count="262"/>
                <participants group_id="P6" count="127"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="24"/>
                <participants group_id="P6" count="16"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator's Discretion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance With Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not Receive Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Study: Week 11 to Week 58</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Participants achieved either EBS remission/MCS response at Week 10 continued into Maintenance Study.</participants>
                <participants group_id="P2" count="0">Participants achieved either EBS remission/MCS response at Week 10 continued into Maintenance Study.</participants>
                <participants group_id="P3" count="0">Participants achieved either EBS remission/MCS response at Week 10 continued into Maintenance Study.</participants>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0">Participants achieved either EBS remission/MCS response at Week 10 continued into Maintenance Study.</participants>
                <participants group_id="P7" count="202">Participants achieved either EBS remission/MCS response at Week 10 continued into Maintenance Study.</participants>
                <participants group_id="P8" count="99">Participants achieved either EBS remission/MCS response at Week 10 continued into Maintenance Study.</participants>
                <participants group_id="P9" count="179">Participants achieved either EBS remission/MCS response at Week 10 continued into Maintenance Study.</participants>
                <participants group_id="P10" count="91">Participants achieved either EBS remission/MCS response at Week 10 continued into Maintenance Study.</participants>
                <participants group_id="P11" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="150"/>
                <participants group_id="P8" count="41"/>
                <participants group_id="P9" count="104"/>
                <participants group_id="P10" count="42"/>
                <participants group_id="P11" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="52"/>
                <participants group_id="P8" count="58"/>
                <participants group_id="P9" count="75"/>
                <participants group_id="P10" count="49"/>
                <participants group_id="P11" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol-specified Disease Worsening</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="34"/>
                <participants group_id="P8" count="49"/>
                <participants group_id="P9" count="53"/>
                <participants group_id="P10" count="39"/>
                <participants group_id="P11" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="10"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator's Discretion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance With Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set for the Induction Study (Cohorts A and B) included all participants who took at least 1 dose of study drug in the Induction Study.</population>
      <group_list>
        <group group_id="B1">
          <title>Induction Study (Cohort A): Filgotinib 200 mg</title>
          <description>Participants in Cohort A (biologic-naive) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Induction Study (Cohort A): Filgotinib 100 mg</title>
          <description>Participants in Cohort A (biologic-naive) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Induction Study (Cohort A): Placebo</title>
          <description>Participants in Cohort A (biologic-naive) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Induction Study (Cohort B): Filgotinib 200 mg</title>
          <description>Participants in Cohort B (biologic-experienced) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Induction Study (Cohort B): Filgotinib 100 mg</title>
          <description>Participants in Cohort B (biologic-experienced) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Induction Study (Cohort B): Placebo</title>
          <description>Participants in Cohort B (biologic-experienced) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="245"/>
            <count group_id="B2" value="277"/>
            <count group_id="B3" value="137"/>
            <count group_id="B4" value="262"/>
            <count group_id="B5" value="285"/>
            <count group_id="B6" value="142"/>
            <count group_id="B7" value="1348"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="234"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="243"/>
                    <measurement group_id="B5" value="264"/>
                    <measurement group_id="B6" value="128"/>
                    <measurement group_id="B7" value="1259"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="114"/>
                    <measurement group_id="B5" value="99"/>
                    <measurement group_id="B6" value="56"/>
                    <measurement group_id="B7" value="561"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="148"/>
                    <measurement group_id="B5" value="186"/>
                    <measurement group_id="B6" value="86"/>
                    <measurement group_id="B7" value="787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Not Permitted = local regulators did not allow collection of race or ethnicity information.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="51"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="322"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="192"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="190"/>
                    <measurement group_id="B5" value="212"/>
                    <measurement group_id="B6" value="98"/>
                    <measurement group_id="B7" value="952"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Permitted</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Not Permitted = local regulators did not allow collection of race or ethnicity information.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <category_list>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="238"/>
                    <measurement group_id="B2" value="269"/>
                    <measurement group_id="B3" value="134"/>
                    <measurement group_id="B4" value="249"/>
                    <measurement group_id="B5" value="273"/>
                    <measurement group_id="B6" value="134"/>
                    <measurement group_id="B7" value="1297"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Permitted</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="58"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Georgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ireland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Induction Study: Percentage of Participants Who Achieved Endoscopy/Bleeding/Stool Frequency (EBS) Remission at Week 10</title>
        <description>EBS remission was defined as an endoscopic subscore of 0 or 1; rectal bleeding subscore of 0; and at least a 1-point decrease in stool frequency from baseline to achieve a subscore of 0 or 1. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration); rectal bleeding subscore range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes; stool frequency subscore range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal. Total score for EBS ranged from 0 to 9 (sum of all subscores), with higher scores indicating more severe disease.</description>
        <time_frame>Week 10</time_frame>
        <population>Full Analysis Set for the Induction study (Cohorts A and B) included all randomized participants who took at least 1 dose of study drug in the corresponding Induction study.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Study (Cohort A): Filgotinib 200 mg</title>
            <description>Participants in Cohort A (biologic-naive) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Induction Study (Cohort A): Filgotinib 100 mg</title>
            <description>Participants in Cohort A (biologic-naive) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Induction Study (Cohort A): Placebo</title>
            <description>Participants in Cohort A (biologic-naive) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Induction Study (Cohort B): Filgotinib 200 mg</title>
            <description>Participants in Cohort B (biologic-experienced) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Induction Study (Cohort B): Filgotinib 100 mg</title>
            <description>Participants in Cohort B (biologic-experienced) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Induction Study (Cohort B): Placebo</title>
            <description>Participants in Cohort B (biologic-experienced) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Study: Percentage of Participants Who Achieved Endoscopy/Bleeding/Stool Frequency (EBS) Remission at Week 10</title>
          <description>EBS remission was defined as an endoscopic subscore of 0 or 1; rectal bleeding subscore of 0; and at least a 1-point decrease in stool frequency from baseline to achieve a subscore of 0 or 1. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration); rectal bleeding subscore range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes; stool frequency subscore range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal. Total score for EBS ranged from 0 to 9 (sum of all subscores), with higher scores indicating more severe disease.</description>
          <population>Full Analysis Set for the Induction study (Cohorts A and B) included all randomized participants who took at least 1 dose of study drug in the corresponding Induction study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="277"/>
                <count group_id="O3" value="137"/>
                <count group_id="O4" value="262"/>
                <count group_id="O5" value="285"/>
                <count group_id="O6" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" lower_limit="20.4" upper_limit="31.8"/>
                    <measurement group_id="O2" value="19.1" lower_limit="14.3" upper_limit="23.9"/>
                    <measurement group_id="O3" value="15.3" lower_limit="8.9" upper_limit="21.7"/>
                    <measurement group_id="O4" value="11.5" lower_limit="7.4" upper_limit="15.5"/>
                    <measurement group_id="O5" value="9.5" lower_limit="5.9" upper_limit="13.0"/>
                    <measurement group_id="O6" value="4.2" lower_limit="0.6" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0157</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel(CMH) test was stratified by concomitant use of oral, systemic corticosteroids (Yes/No) and immunomodulators (Yes/No) at Day 1.</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>10.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.1</ci_lower_limit>
            <ci_upper_limit>19.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3379</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by concomitant use of oral, systemic corticosteroids (Yes or No) and of immunomodulators (Yes or No) at Day 1.</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>3.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.3</ci_lower_limit>
            <ci_upper_limit>12.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0103</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH was stratified by concomitant use of corticosteroids and of immunomodulators at Day 1, and number of prior exposure to biologic agent (≤1,&gt;1).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>7.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.6</ci_lower_limit>
            <ci_upper_limit>12.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0645</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH was stratified by concomitant use of corticosteroids and of immunomodulators at Day 1, and number of prior exposure to biologic agent (≤1,&gt;1).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>5.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0</ci_lower_limit>
            <ci_upper_limit>10.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maintenance Study: Percentage of Participants Who Achieved EBS Remission at Week 58</title>
        <description>EBS remission was defined as an endoscopic subscore of 0 or 1; rectal bleeding subscore of 0; and at least a 1-point decrease in stool frequency from baseline to achieve a subscore of 0 or 1. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration); rectal bleeding subscore range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes; stool frequency subscore range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal. Total score for EBS ranged from 0 to 9 (sum of all subscores), with higher scores indicating more severe disease.</description>
        <time_frame>Week 58</time_frame>
        <population>Full Analysis Set for the Maintenance Study included all participants randomized to either the filgotinib 200 mg or filgotinib 100 mg treatment groups in the Induction Study (Cohorts A and B) who achieved EBS remission or MCS response at Week 10, were rerandomized, and took at least 1 dose of study drug in the Maintenance Study.</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg</title>
            <description>Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
          <group group_id="O2">
            <title>Maintenance Study: Placebo From Induction Filgotinib 200 mg</title>
            <description>Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
          <group group_id="O3">
            <title>Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg</title>
            <description>Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
          <group group_id="O4">
            <title>Maintenance Study: Placebo From Induction Filgotinib 100 mg</title>
            <description>Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were rerandomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Study: Percentage of Participants Who Achieved EBS Remission at Week 58</title>
          <description>EBS remission was defined as an endoscopic subscore of 0 or 1; rectal bleeding subscore of 0; and at least a 1-point decrease in stool frequency from baseline to achieve a subscore of 0 or 1. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration); rectal bleeding subscore range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes; stool frequency subscore range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal. Total score for EBS ranged from 0 to 9 (sum of all subscores), with higher scores indicating more severe disease.</description>
          <population>Full Analysis Set for the Maintenance Study included all participants randomized to either the filgotinib 200 mg or filgotinib 100 mg treatment groups in the Induction Study (Cohorts A and B) who achieved EBS remission or MCS response at Week 10, were rerandomized, and took at least 1 dose of study drug in the Maintenance Study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="172"/>
                <count group_id="O4" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.2" lower_limit="30.2" upper_limit="44.2"/>
                    <measurement group_id="O2" value="11.2" lower_limit="4.5" upper_limit="18.0"/>
                    <measurement group_id="O3" value="23.8" lower_limit="17.2" upper_limit="30.5"/>
                    <measurement group_id="O4" value="13.5" lower_limit="5.8" upper_limit="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>26.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.0</ci_lower_limit>
            <ci_upper_limit>35.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0420</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>10.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0</ci_lower_limit>
            <ci_upper_limit>20.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Study: Percentage of Participants Who Achieved MCS Remission at Week 10</title>
        <description>MCS remission was defined as having a MCS of 2 or less and no single subscore higher than 1. The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease [spontaneous bleeding, ulceration]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and physician's global assessment (PGA). The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.</description>
        <time_frame>Week 10</time_frame>
        <population>Participants in the Full Analysis Set for the Induction Study (Cohorts A and B) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Study (Cohort A): Filgotinib 200 mg</title>
            <description>Participants in Cohort A (biologic-naive) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Induction Study (Cohort A): Filgotinib 100 mg</title>
            <description>Participants in Cohort A (biologic-naive) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Induction Study (Cohort A): Placebo</title>
            <description>Participants in Cohort A (biologic-naive) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Induction Study (Cohort B): Filgotinib 200 mg</title>
            <description>Participants in Cohort B (biologic-experienced) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Induction Study (Cohort B): Filgotinib 100 mg</title>
            <description>Participants in Cohort B (biologic-experienced) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Induction Study (Cohort B): Placebo</title>
            <description>Participants in Cohort B (biologic-experienced) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Study: Percentage of Participants Who Achieved MCS Remission at Week 10</title>
          <description>MCS remission was defined as having a MCS of 2 or less and no single subscore higher than 1. The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease [spontaneous bleeding, ulceration]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and physician's global assessment (PGA). The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.</description>
          <population>Participants in the Full Analysis Set for the Induction Study (Cohorts A and B) were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="277"/>
                <count group_id="O3" value="137"/>
                <count group_id="O4" value="262"/>
                <count group_id="O5" value="285"/>
                <count group_id="O6" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" lower_limit="18.9" upper_limit="30.1"/>
                    <measurement group_id="O2" value="17.0" lower_limit="12.4" upper_limit="21.6"/>
                    <measurement group_id="O3" value="12.4" lower_limit="6.5" upper_limit="18.3"/>
                    <measurement group_id="O4" value="9.5" lower_limit="5.8" upper_limit="13.3"/>
                    <measurement group_id="O5" value="6.0" lower_limit="3.0" upper_limit="8.9"/>
                    <measurement group_id="O6" value="4.2" lower_limit="0.6" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0053</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test is stratified by concomitant use of oral, systemic corticosteroids (Yes or No) and of immunomodulators (Yes or No) at Day 1.</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>12.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.8</ci_lower_limit>
            <ci_upper_limit>20.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2295</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test is stratified by concomitant use of oral, systemic corticosteroids (Yes or No) and of immunomodulators (Yes or No) at Day 1.</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>4.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>12.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0393</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH was stratified by concomitant use of corticosteroids and of immunomodulators at Day 1, and number of prior exposure to biologic agent (≤1,&gt;1).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>5.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>10.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5308</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH was stratified by concomitant use of corticosteroids and of immunomodulators at Day 1, and number of prior exposure to biologic agent (≤1,&gt;1).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>6.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Study: Percentage of Participants Who Achieved an Endoscopic Subscore of 0 at Week 10</title>
        <description>Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).</description>
        <time_frame>Week 10</time_frame>
        <population>Participants in the Full Analysis Set for the Induction Study (Cohorts A and B) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Study (Cohort A): Filgotinib 200 mg</title>
            <description>Participants in Cohort A (biologic-naive) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Induction Study (Cohort A): Filgotinib 100 mg</title>
            <description>Participants in Cohort A (biologic-naive) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Induction Study (Cohort A): Placebo</title>
            <description>Participants in Cohort A (biologic-naive) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Induction Study (Cohort B): Filgotinib 200 mg</title>
            <description>Participants in Cohort B (biologic-experienced) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Induction Study (Cohort B): Filgotinib 100 mg</title>
            <description>Participants in Cohort B (biologic-experienced) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Induction Study (Cohort B): Placebo</title>
            <description>Participants in Cohort B (biologic-experienced) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Study: Percentage of Participants Who Achieved an Endoscopic Subscore of 0 at Week 10</title>
          <description>Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).</description>
          <population>Participants in the Full Analysis Set for the Induction Study (Cohorts A and B) were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="277"/>
                <count group_id="O3" value="137"/>
                <count group_id="O4" value="262"/>
                <count group_id="O5" value="285"/>
                <count group_id="O6" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="7.9" upper_limit="16.6"/>
                    <measurement group_id="O2" value="5.8" lower_limit="2.8" upper_limit="8.7"/>
                    <measurement group_id="O3" value="3.6" lower_limit="0.1" upper_limit="7.2"/>
                    <measurement group_id="O4" value="3.4" lower_limit="1.0" upper_limit="5.8"/>
                    <measurement group_id="O5" value="2.1" lower_limit="0.3" upper_limit="3.9"/>
                    <measurement group_id="O6" value="2.1" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0047</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test is stratified by concomitant use of oral, systemic corticosteroids (Yes or No) and of immunomodulators (Yes or No) at Day 1.</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>8.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.9</ci_lower_limit>
            <ci_upper_limit>14.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3495</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test is stratified by concomitant use of oral, systemic corticosteroids (Yes or No) and of immunomodulators (Yes or No) at Day 1.</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>6.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4269</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH was stratified by concomitant use of corticosteroids and of immunomodulators at Day 1, and number of prior exposure to biologic agent (≤1,&gt;1).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>5.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9987</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH was stratified by concomitant use of corticosteroids and of immunomodulators at Day 1, and number of prior exposure to biologic agent (≤1,&gt;1).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>-0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Study: Percentage of Participants Who Achieved Geboes Histologic Remission at Week 10</title>
        <description>Geboes histologic remission was assessed using the Geboes histologic scores for evaluation of disease severity in ulcerative colitis and classifies histologic changes. Remission was defined as having Grade 0 of &lt;= 0.3, Grade 1 of &lt;= 1.1, Grade 2A of &lt;= 2A.3, Grade 2B of 2B.0, Grade 3 of 3.0, Grade 4 of 4.0, and Grade 5 of 5.0. Possible scores are Grade 0: Architectural changes (0.0=No abnormality to 0.3=Severe diffuse or multifocal abnormalities); Grade 1: Chronic inflammatory infiltrate (1.0=No increase to 1.3=Marked increase); Grade 2A: Eosinophils in lamina propria (2A.0=No increase to 2A.3-=Marked increase; Grade 2B: Neutrophils in lamina propria (2B.0= No increase to 2B.3=Marked increase); Grade 3: Neutrophils in epithelium (3.0=None to 3.3=&gt;50% crypts involved); Grade 4: Crypt destruction (4.0=none to 4.3=Unequivocal crypt destruction), and Grade 5: Erosions and ulcerations: (5.0=No erosion, ulceration or granulation to 5.4=Ulcer or granulation tissue).</description>
        <time_frame>Week 10</time_frame>
        <population>Participants in the Full Analysis Set for the Induction study (Cohorts A and B) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Study (Cohort A): Filgotinib 200 mg</title>
            <description>Participants in Cohort A (biologic-naive) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Induction Study (Cohort A): Filgotinib 100 mg</title>
            <description>Participants in Cohort A (biologic-naive) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Induction Study (Cohort A): Placebo</title>
            <description>Participants in Cohort A (biologic-naive) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Induction Study (Cohort B): Filgotinib 200 mg</title>
            <description>Participants in Cohort B (biologic-experienced) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Induction Study (Cohort B): Filgotinib 100 mg</title>
            <description>Participants in Cohort B (biologic-experienced) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Induction Study (Cohort B): Placebo</title>
            <description>Participants in Cohort B (biologic-experienced) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Study: Percentage of Participants Who Achieved Geboes Histologic Remission at Week 10</title>
          <description>Geboes histologic remission was assessed using the Geboes histologic scores for evaluation of disease severity in ulcerative colitis and classifies histologic changes. Remission was defined as having Grade 0 of &lt;= 0.3, Grade 1 of &lt;= 1.1, Grade 2A of &lt;= 2A.3, Grade 2B of 2B.0, Grade 3 of 3.0, Grade 4 of 4.0, and Grade 5 of 5.0. Possible scores are Grade 0: Architectural changes (0.0=No abnormality to 0.3=Severe diffuse or multifocal abnormalities); Grade 1: Chronic inflammatory infiltrate (1.0=No increase to 1.3=Marked increase); Grade 2A: Eosinophils in lamina propria (2A.0=No increase to 2A.3-=Marked increase; Grade 2B: Neutrophils in lamina propria (2B.0= No increase to 2B.3=Marked increase); Grade 3: Neutrophils in epithelium (3.0=None to 3.3=&gt;50% crypts involved); Grade 4: Crypt destruction (4.0=none to 4.3=Unequivocal crypt destruction), and Grade 5: Erosions and ulcerations: (5.0=No erosion, ulceration or granulation to 5.4=Ulcer or granulation tissue).</description>
          <population>Participants in the Full Analysis Set for the Induction study (Cohorts A and B) were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="277"/>
                <count group_id="O3" value="137"/>
                <count group_id="O4" value="262"/>
                <count group_id="O5" value="285"/>
                <count group_id="O6" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1" lower_limit="28.9" upper_limit="41.3"/>
                    <measurement group_id="O2" value="23.8" lower_limit="18.6" upper_limit="29.0"/>
                    <measurement group_id="O3" value="16.1" lower_limit="9.5" upper_limit="22.6"/>
                    <measurement group_id="O4" value="19.8" lower_limit="14.8" upper_limit="24.9"/>
                    <measurement group_id="O5" value="13.7" lower_limit="9.5" upper_limit="17.8"/>
                    <measurement group_id="O6" value="8.5" lower_limit="3.5" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test is stratified by concomitant use of oral, systemic corticosteroids (Yes or No) and of immunomodulators (Yes or No) at Day 1.</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>19.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.9</ci_lower_limit>
            <ci_upper_limit>28.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0672</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test is stratified by concomitant use of oral, systemic corticosteroids (Yes or No) and of immunomodulators (Yes or No) at Day 1.</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>7.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>16.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0019</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH was stratified by concomitant use of corticosteroids and of immunomodulators at Day 1, and number of prior exposure to biologic agent (≤1,&gt;1).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>11.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.2</ci_lower_limit>
            <ci_upper_limit>18.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1286</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH was stratified by concomitant use of corticosteroids and of immunomodulators at Day 1, and number of prior exposure to biologic agent (≤1,&gt;1).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>5.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>11.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Study: Percentage of Participants Who Achieved MCS Remission (Alternative Definition) at Week 10</title>
        <description>MCS remission (alternative definition) was defined as having rectal bleeding, stool frequency, and PGA subscores of 0 and an endoscopic subscore of 0 or 1; overall MCS of ≤ 1. MCS possible subscores: rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), PGA subscore (range: 0 to 3 with higher score indicating the severe disease), and an endoscopic subscore (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease [spontaneous bleeding, ulceration]. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.</description>
        <time_frame>Week 10</time_frame>
        <population>Participants in the Full Analysis Set for the Induction Study (Cohorts A and B) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Study (Cohort A): Filgotinib 200 mg</title>
            <description>Participants in Cohort A (biologic-naive) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Induction Study (Cohort A): Filgotinib 100 mg</title>
            <description>Participants in Cohort A (biologic-naive) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Induction Study (Cohort A): Placebo</title>
            <description>Participants in Cohort A (biologic-naive) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Induction Study (Cohort B): Filgotinib 200 mg</title>
            <description>Participants in Cohort B (biologic-experienced) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Induction Study (Cohort B): Filgotinib 100 mg</title>
            <description>Participants in Cohort B (biologic-experienced) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Induction Study (Cohort B): Placebo</title>
            <description>Participants in Cohort B (biologic-experienced) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Study: Percentage of Participants Who Achieved MCS Remission (Alternative Definition) at Week 10</title>
          <description>MCS remission (alternative definition) was defined as having rectal bleeding, stool frequency, and PGA subscores of 0 and an endoscopic subscore of 0 or 1; overall MCS of ≤ 1. MCS possible subscores: rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), PGA subscore (range: 0 to 3 with higher score indicating the severe disease), and an endoscopic subscore (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease [spontaneous bleeding, ulceration]. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.</description>
          <population>Participants in the Full Analysis Set for the Induction Study (Cohorts A and B) were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="277"/>
                <count group_id="O3" value="137"/>
                <count group_id="O4" value="262"/>
                <count group_id="O5" value="285"/>
                <count group_id="O6" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="7.9" upper_limit="16.6"/>
                    <measurement group_id="O2" value="8.7" lower_limit="5.2" upper_limit="12.2"/>
                    <measurement group_id="O3" value="4.4" lower_limit="0.6" upper_limit="8.2"/>
                    <measurement group_id="O4" value="3.8" lower_limit="1.3" upper_limit="6.3"/>
                    <measurement group_id="O5" value="2.1" lower_limit="0.3" upper_limit="3.9"/>
                    <measurement group_id="O6" value="2.1" lower_limit="0.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0105</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test is stratified by concomitant use of oral, systemic corticosteroids (Yes or No) and of immunomodulators (Yes or No) at Day 1</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>7.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.9</ci_lower_limit>
            <ci_upper_limit>13.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1062</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test is stratified by concomitant use of oral, systemic corticosteroids (Yes or No) and of immunomodulators (Yes or No) at Day 1</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>4.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>9.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3084</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH was stratified by concomitant use of corticosteroids and of immunomodulators at Day 1, and number of prior exposure to biologic agent (≤1,&gt;1).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>5.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9109</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH was stratified by concomitant use of corticosteroids and of immunomodulators at Day 1, and number of prior exposure to biologic agent (≤1,&gt;1).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>-0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Study: Pharmacokinetic (PK) Parameter: Cmax of Filgotinib and Its Metabolite GS-829845</title>
        <description>Cmax is defined as the maximum observed concentration of drug.</description>
        <time_frame>Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10</time_frame>
        <population>PK Substudy Analysis Set included all randomized participants who took at least 1 dose of filgotinib, participated in the PK substudy, and had at least 1 nonmissing intensive concentration value for filgotinib and/or GS-829845 with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Study (Cohort A): Filgotinib 200 mg</title>
            <description>Participants in Cohort A (biologic-naive) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Induction Study (Cohort A): Filgotinib 100 mg</title>
            <description>Participants in Cohort A (biologic-naive) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Induction Study (Cohort B): Filgotinib 200 mg</title>
            <description>Participants in Cohort B (biologic-experienced) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Induction Study (Cohort B): Filgotinib 100 mg</title>
            <description>Participants in Cohort B (biologic-experienced) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Study: Pharmacokinetic (PK) Parameter: Cmax of Filgotinib and Its Metabolite GS-829845</title>
          <description>Cmax is defined as the maximum observed concentration of drug.</description>
          <population>PK Substudy Analysis Set included all randomized participants who took at least 1 dose of filgotinib, participated in the PK substudy, and had at least 1 nonmissing intensive concentration value for filgotinib and/or GS-829845 with available data were analyzed.</population>
          <units>nanograms per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Filgotinib</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1746.3" spread="1244.05"/>
                    <measurement group_id="O2" value="725.1" spread="313.36"/>
                    <measurement group_id="O3" value="2283.3" spread="1012.03"/>
                    <measurement group_id="O4" value="977.9" spread="403.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite GS-829845</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3227.5" spread="1204.50"/>
                    <measurement group_id="O2" value="1812.2" spread="701.46"/>
                    <measurement group_id="O3" value="4373.3" spread="1121.58"/>
                    <measurement group_id="O4" value="2002.9" spread="598.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Study: PK Parameter: Tmax of Filgotinib and Its Metabolite GS-829845</title>
        <description>Tmax is defined as the time to reach maximum observed concentration of drug.</description>
        <time_frame>Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10</time_frame>
        <population>Participants in the PK Substudy Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Study (Cohort A): Filgotinib 200 mg</title>
            <description>Participants in Cohort A (biologic-naive) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Induction Study (Cohort A): Filgotinib 100 mg</title>
            <description>Participants in Cohort A (biologic-naive) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Induction Study (Cohort B): Filgotinib 200 mg</title>
            <description>Participants in Cohort B (biologic-experienced) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Induction Study (Cohort B): Filgotinib 100 mg</title>
            <description>Participants in Cohort B (biologic-experienced) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Study: PK Parameter: Tmax of Filgotinib and Its Metabolite GS-829845</title>
          <description>Tmax is defined as the time to reach maximum observed concentration of drug.</description>
          <population>Participants in the PK Substudy Analysis Set with available data were analyzed.</population>
          <units>hour (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Filgotinib</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="0.75" upper_limit="2.00"/>
                    <measurement group_id="O2" value="0.75" lower_limit="0.50" upper_limit="3.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.50" upper_limit="2.25"/>
                    <measurement group_id="O4" value="0.57" lower_limit="0.42" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite GS-829845</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.76" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="3.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="3.02" lower_limit="2.13" upper_limit="6.00"/>
                    <measurement group_id="O4" value="3.00" lower_limit="1.03" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Study: PK Parameter: AUCtau of Filgotinib and Its Metabolite GS-82984</title>
        <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).</description>
        <time_frame>Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10</time_frame>
        <population>Participants in the PK Substudy Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Study (Cohort A): Filgotinib 200 mg</title>
            <description>Participants in Cohort A (biologic-naive) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Induction Study (Cohort A): Filgotinib 100 mg</title>
            <description>Participants in Cohort A (biologic-naive) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Induction Study (Cohort B): Filgotinib 200 mg</title>
            <description>Participants in Cohort B (biologic-experienced) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Induction Study (Cohort B): Filgotinib 100 mg</title>
            <description>Participants in Cohort B (biologic-experienced) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Study: PK Parameter: AUCtau of Filgotinib and Its Metabolite GS-82984</title>
          <description>AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).</description>
          <population>Participants in the PK Substudy Analysis Set with available data were analyzed.</population>
          <units>hour*nanograms per milliliter (h*ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Filgotinib</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5501.3" spread="1956.39"/>
                    <measurement group_id="O2" value="1909.3" spread="788.13"/>
                    <measurement group_id="O3" value="6475.6" spread="1643.00"/>
                    <measurement group_id="O4" value="2492.3" spread="852.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite GS-829845</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57982.0" spread="17767.52"/>
                    <measurement group_id="O2" value="31187.9" spread="11858.78"/>
                    <measurement group_id="O3" value="80208.6" spread="25096.57"/>
                    <measurement group_id="O4" value="36075.6" spread="13396.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Study: PK Parameter: AUClast of Filgotinib and Its Metabolite GS-82984</title>
        <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration.</description>
        <time_frame>Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10</time_frame>
        <population>Participants in the PK Substudy Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Study (Cohort A): Filgotinib 200 mg</title>
            <description>Participants in Cohort A (biologic-naive) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Induction Study (Cohort A): Filgotinib 100 mg</title>
            <description>Participants in Cohort A (biologic-naive) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Induction Study (Cohort B): Filgotinib 200 mg</title>
            <description>Participants in Cohort B (biologic-experienced) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Induction Study (Cohort B): Filgotinib 100 mg</title>
            <description>Participants in Cohort B (biologic-experienced) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Study: PK Parameter: AUClast of Filgotinib and Its Metabolite GS-82984</title>
          <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration.</description>
          <population>Participants in the PK Substudy Analysis Set with available data were analyzed.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Filgotinib</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5537.3" spread="1900.93"/>
                    <measurement group_id="O2" value="1881.9" spread="797.51"/>
                    <measurement group_id="O3" value="6743.1" spread="1743.68"/>
                    <measurement group_id="O4" value="2420.3" spread="837.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite GS-829845</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60938.4" spread="6961.77"/>
                    <measurement group_id="O2" value="30643.2" spread="12935.37"/>
                    <measurement group_id="O3" value="79286.3" spread="27968.49"/>
                    <measurement group_id="O4" value="34385.6" spread="15160.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction Study: PK Parameter: Ctau of Filgotinib and Its Metabolite GS-82984</title>
        <description>Ctau is defined as the observed drug concentration at the end of the dosing interval.</description>
        <time_frame>Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10</time_frame>
        <population>Participants in the PK Substudy Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Study (Cohort A): Filgotinib 200 mg</title>
            <description>Participants in Cohort A (biologic-naive) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Induction Study (Cohort A): Filgotinib 100 mg</title>
            <description>Participants in Cohort A (biologic-naive) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Induction Study (Cohort B): Filgotinib 200 mg</title>
            <description>Participants in Cohort B (biologic-experienced) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Induction Study (Cohort B): Filgotinib 100 mg</title>
            <description>Participants in Cohort B (biologic-experienced) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Induction Study: PK Parameter: Ctau of Filgotinib and Its Metabolite GS-82984</title>
          <description>Ctau is defined as the observed drug concentration at the end of the dosing interval.</description>
          <population>Participants in the PK Substudy Analysis Set with available data were analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Filgotinib</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="4.74"/>
                    <measurement group_id="O2" value="4.5" spread="3.61"/>
                    <measurement group_id="O3" value="36.6" spread="79.06"/>
                    <measurement group_id="O4" value="4.1" spread="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite GS-829845</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2050.0" spread="493.66"/>
                    <measurement group_id="O2" value="934.8" spread="372.68"/>
                    <measurement group_id="O3" value="2581.3" spread="777.07"/>
                    <measurement group_id="O4" value="1062.8" spread="463.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Study: Percentage of Participants Who Achieved MCS Remission at Week 58</title>
        <description>MCS remission was defined as having a MCS of 2 or less and no single subscore higher than 1. The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease [spontaneous bleeding, ulceration]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and PGA. The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.</description>
        <time_frame>Week 58</time_frame>
        <population>Participants in the Full Analysis Set for the Maintenance Study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg</title>
            <description>Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
          <group group_id="O2">
            <title>Maintenance Study: Placebo From Induction Filgotinib 200 mg</title>
            <description>Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
          <group group_id="O3">
            <title>Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg</title>
            <description>Participants in the Filgotinib 100 mg arm) who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
          <group group_id="O4">
            <title>Maintenance Study: Placebo From Induction Filgotinib 100 mg</title>
            <description>Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were rerandomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Study: Percentage of Participants Who Achieved MCS Remission at Week 58</title>
          <description>MCS remission was defined as having a MCS of 2 or less and no single subscore higher than 1. The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease [spontaneous bleeding, ulceration]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and PGA. The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.</description>
          <population>Participants in the Full Analysis Set for the Maintenance Study were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="172"/>
                <count group_id="O4" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7" lower_limit="27.8" upper_limit="41.5"/>
                    <measurement group_id="O2" value="9.2" lower_limit="3.0" upper_limit="15.4"/>
                    <measurement group_id="O3" value="22.7" lower_limit="16.1" upper_limit="29.2"/>
                    <measurement group_id="O4" value="13.5" lower_limit="5.8" upper_limit="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>25.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.0</ci_lower_limit>
            <ci_upper_limit>35.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0658</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>9.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>19.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Study: Percentage of Participants Who Achieved Sustained EBS Remission at Week 58</title>
        <description>Sustained EBS remission was defined as having achieved EBS remission at both Weeks 10 and 58.</description>
        <time_frame>Week 58</time_frame>
        <population>Participants in the Full Analysis Set for the Maintenance Study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg</title>
            <description>Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
          <group group_id="O2">
            <title>Maintenance Study: Placebo From Induction Filgotinib 200 mg</title>
            <description>Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
          <group group_id="O3">
            <title>Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg</title>
            <description>Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
          <group group_id="O4">
            <title>Maintenance Study: Placebo From Induction Filgotinib 100 mg</title>
            <description>Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were rerandomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Study: Percentage of Participants Who Achieved Sustained EBS Remission at Week 58</title>
          <description>Sustained EBS remission was defined as having achieved EBS remission at both Weeks 10 and 58.</description>
          <population>Participants in the Full Analysis Set for the Maintenance Study were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="172"/>
                <count group_id="O4" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" lower_limit="12.5" upper_limit="23.7"/>
                    <measurement group_id="O2" value="5.1" lower_limit="0.2" upper_limit="10.0"/>
                    <measurement group_id="O3" value="8.7" lower_limit="4.2" upper_limit="13.2"/>
                    <measurement group_id="O4" value="7.9" lower_limit="1.7" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0024</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>13.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.3</ci_lower_limit>
            <ci_upper_limit>20.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7951</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.0</ci_lower_limit>
            <ci_upper_limit>8.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Study: Percentage of Participants Who Achieved 6-Month Corticosteroid-Free EBS Remission at Week 58</title>
        <description>Six-month corticosteroid-free EBS remission at Week 58 was defined as achieving EBS remission with no corticosteroid use for the indication of ulcerative colitis for at least 6 months prior to Week 58.</description>
        <time_frame>Week 58</time_frame>
        <population>Participants in the Full Analysis Set who were on corticosteroids at Maintenance Study baseline were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg</title>
            <description>Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
          <group group_id="O2">
            <title>Maintenance Study: Placebo From Induction Filgotinib 200 mg</title>
            <description>Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
          <group group_id="O3">
            <title>Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg</title>
            <description>Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
          <group group_id="O4">
            <title>Maintenance Study: Placebo From Induction Filgotinib 100 mg</title>
            <description>Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were rerandomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Study: Percentage of Participants Who Achieved 6-Month Corticosteroid-Free EBS Remission at Week 58</title>
          <description>Six-month corticosteroid-free EBS remission at Week 58 was defined as achieving EBS remission with no corticosteroid use for the indication of ulcerative colitis for at least 6 months prior to Week 58.</description>
          <population>Participants in the Full Analysis Set who were on corticosteroids at Maintenance Study baseline were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" lower_limit="17.5" upper_limit="36.8"/>
                    <measurement group_id="O2" value="6.4" lower_limit="0.0" upper_limit="14.4"/>
                    <measurement group_id="O3" value="13.6" lower_limit="5.5" upper_limit="21.7"/>
                    <measurement group_id="O4" value="5.4" lower_limit="0.0" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0055</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>20.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.7</ci_lower_limit>
            <ci_upper_limit>33.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1265</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>8.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>20.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Study: Percentage of Participants Who Achieved Endoscopic Subscore of 0 at Weeks 58</title>
        <description>Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).</description>
        <time_frame>Week 58</time_frame>
        <population>Participants in the Full Analysis Set for the Maintenance Study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg</title>
            <description>Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
          <group group_id="O2">
            <title>Maintenance Study: Placebo From Induction Filgotinib 200 mg</title>
            <description>Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
          <group group_id="O3">
            <title>Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg</title>
            <description>Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
          <group group_id="O4">
            <title>Maintenance Study: Placebo From Induction Filgotinib 100 mg</title>
            <description>Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were rerandomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Study: Percentage of Participants Who Achieved Endoscopic Subscore of 0 at Weeks 58</title>
          <description>Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).</description>
          <population>Participants in the Full Analysis Set for the Maintenance Study were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="172"/>
                <count group_id="O4" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="10.3" upper_limit="20.9"/>
                    <measurement group_id="O2" value="6.1" lower_limit="0.9" upper_limit="11.4"/>
                    <measurement group_id="O3" value="13.4" lower_limit="8.0" upper_limit="18.7"/>
                    <measurement group_id="O4" value="7.9" lower_limit="1.7" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0157</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>9.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.8</ci_lower_limit>
            <ci_upper_limit>17.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1808</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>5.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>13.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Study: Percentage of Participants Who Achieved Geboes Histologic Remission at Week 58</title>
        <description>Geboes histologic remission was assessed using the Geboes histologic scores for evaluation of disease severity in ulcerative colitis and classifies histologic changes. Remission was defined as having Grade 0 of &lt;= 0.3, Grade 1 of &lt;= 1.1, Grade 2A of &lt;= 2A.3, Grade 2B of 2B.0, Grade 3 of 3.0, Grade 4 of 4.0, and Grade 5 of 5.0. Possible scores are Grade 0: Architectural changes (0.0=No abnormality to 0.3=Severe diffuse or multifocal abnormalities); Grade 1: Chronic inflammatory infiltrate (1.0=No increase to 1.3=Marked increase); Grade 2A: Eosinophils in lamina propria (2A.0=No increase to 2A.3-=Marked increase; Grade 2B: Neutrophils in lamina propria (2B.0= No increase to 2B.3=Marked increase); Grade 3: Neutrophils in epithelium (3.0=None to 3.3=&gt;50% crypts involved); Grade 4: Crypt destruction (4.0=none to 4.3=Unequivocal crypt destruction), and Grade 5: Erosions and ulcerations: (5.0=No erosion, ulceration or granulation to 5.4=Ulcer or granulation tissue).</description>
        <time_frame>Week 58</time_frame>
        <population>Participants in the Full Analysis Set for the Maintenance Study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg</title>
            <description>Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
          <group group_id="O2">
            <title>Maintenance Study: Placebo From Induction Filgotinib 200 mg</title>
            <description>Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
          <group group_id="O3">
            <title>Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg</title>
            <description>Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
          <group group_id="O4">
            <title>Maintenance Study: Placebo From Induction Filgotinib 100 mg</title>
            <description>Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were rerandomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Study: Percentage of Participants Who Achieved Geboes Histologic Remission at Week 58</title>
          <description>Geboes histologic remission was assessed using the Geboes histologic scores for evaluation of disease severity in ulcerative colitis and classifies histologic changes. Remission was defined as having Grade 0 of &lt;= 0.3, Grade 1 of &lt;= 1.1, Grade 2A of &lt;= 2A.3, Grade 2B of 2B.0, Grade 3 of 3.0, Grade 4 of 4.0, and Grade 5 of 5.0. Possible scores are Grade 0: Architectural changes (0.0=No abnormality to 0.3=Severe diffuse or multifocal abnormalities); Grade 1: Chronic inflammatory infiltrate (1.0=No increase to 1.3=Marked increase); Grade 2A: Eosinophils in lamina propria (2A.0=No increase to 2A.3-=Marked increase; Grade 2B: Neutrophils in lamina propria (2B.0= No increase to 2B.3=Marked increase); Grade 3: Neutrophils in epithelium (3.0=None to 3.3=&gt;50% crypts involved); Grade 4: Crypt destruction (4.0=none to 4.3=Unequivocal crypt destruction), and Grade 5: Erosions and ulcerations: (5.0=No erosion, ulceration or granulation to 5.4=Ulcer or granulation tissue).</description>
          <population>Participants in the Full Analysis Set for the Maintenance Study were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="172"/>
                <count group_id="O4" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2" lower_limit="31.2" upper_limit="45.2"/>
                    <measurement group_id="O2" value="13.3" lower_limit="6.0" upper_limit="20.5"/>
                    <measurement group_id="O3" value="27.9" lower_limit="20.9" upper_limit="34.9"/>
                    <measurement group_id="O4" value="18.0" lower_limit="9.4" upper_limit="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>24.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.6</ci_lower_limit>
            <ci_upper_limit>35.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0521</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>9.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>21.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Study: Percentage of Participants Who Achieved MCS Remission (Alternative Definition) at Week 58</title>
        <description>MCS remission (alternative definition) was defined as having rectal bleeding, stool frequency, and PGA subscores of 0 and an endoscopic subscore of 0 or 1; overall MCS of ≤ 1. MCS possible subscores: rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), PGA subscore (range: 0 to 3 with higher score indicating the severe disease), and an endoscopic subscore (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease [spontaneous bleeding, ulceration]. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.</description>
        <time_frame>Week 58</time_frame>
        <population>Participants in the Full Analysis Set for the Maintenance Study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg</title>
            <description>Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
          <group group_id="O2">
            <title>Maintenance Study: Placebo From Induction Filgotinib 200 mg</title>
            <description>Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
          <group group_id="O3">
            <title>Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg</title>
            <description>Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
          <group group_id="O4">
            <title>Maintenance Study: Placebo From Induction Filgotinib 100 mg</title>
            <description>Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were rerandomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Study: Percentage of Participants Who Achieved MCS Remission (Alternative Definition) at Week 58</title>
          <description>MCS remission (alternative definition) was defined as having rectal bleeding, stool frequency, and PGA subscores of 0 and an endoscopic subscore of 0 or 1; overall MCS of ≤ 1. MCS possible subscores: rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), PGA subscore (range: 0 to 3 with higher score indicating the severe disease), and an endoscopic subscore (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease [spontaneous bleeding, ulceration]. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.</description>
          <population>Participants in the Full Analysis Set for the Maintenance Study were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="172"/>
                <count group_id="O4" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" lower_limit="16.1" upper_limit="28.1"/>
                    <measurement group_id="O2" value="6.1" lower_limit="0.9" upper_limit="11.4"/>
                    <measurement group_id="O3" value="12.2" lower_limit="7.0" upper_limit="17.4"/>
                    <measurement group_id="O4" value="7.9" lower_limit="1.7" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>16.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.8</ci_lower_limit>
            <ci_upper_limit>24.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2946</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>4.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>12.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maintenance Study: Plasma Concentration of Filgotinib and Its Metabolite GS-829845</title>
        <description>Plasma concentration is defined as the measured drug concentration of filgotinib and its metabolite GS-829845. Lower limit of quantitation (LLOQ) was defined as 1 ng/mL for analyte filgotinib and 2 ng/mL for analyte GS-829845.</description>
        <time_frame>Week 26 (any Time) and Week 58 (predose)</time_frame>
        <population>PK Analysis Set included all participants in the Safety Analysis Set who who took at least 1 dose of filgotinib and had at least 1 nonmissing plasma concentration value for filgotinib and/or its metabolite GS-829845 with available data were analyzed. Data was not collected for the Maintenance Study Placebo arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg</title>
            <description>Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
          <group group_id="O2">
            <title>Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg</title>
            <description>Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for an additional 47 weeks (up to Week 58).</description>
          </group>
        </group_list>
        <measure>
          <title>Maintenance Study: Plasma Concentration of Filgotinib and Its Metabolite GS-829845</title>
          <description>Plasma concentration is defined as the measured drug concentration of filgotinib and its metabolite GS-829845. Lower limit of quantitation (LLOQ) was defined as 1 ng/mL for analyte filgotinib and 2 ng/mL for analyte GS-829845.</description>
          <population>PK Analysis Set included all participants in the Safety Analysis Set who who took at least 1 dose of filgotinib and had at least 1 nonmissing plasma concentration value for filgotinib and/or its metabolite GS-829845 with available data were analyzed. Data was not collected for the Maintenance Study Placebo arms.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Filgotinib: Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                    <count group_id="O2" value="127"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="5.0" upper_limit="25.8"/>
                    <measurement group_id="O2" value="4.4" lower_limit="2.5" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Filgotinib: Week 58</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="NA" upper_limit="9.1">Value was below the limit of quantitation.</measurement>
                    <measurement group_id="O2" value="4.1" lower_limit="NA" upper_limit="6.9">Value was below the limit of quantitation.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite GS-829845: Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="170"/>
                    <count group_id="O2" value="130"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2495.0" lower_limit="1940.0" upper_limit="3010.0"/>
                    <measurement group_id="O2" value="1180.0" lower_limit="852.0" upper_limit="1550.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite GS-829845: Week 58</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1930.0" lower_limit="1320.0" upper_limit="2630.0"/>
                    <measurement group_id="O2" value="973.5" lower_limit="773.0" upper_limit="1350.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Induction Study: first dose date up to one day before the Maintenance first dose date or last dose date whichever is earlier (maximum 17 weeks) plus 30 days, Maintenance study: First dose to the last dose in the Maintenance Study (maximum 51 weeks) plus 30 days</time_frame>
      <desc>Adverse Events: Safety Analysis Set for the study included all participants who took at least 1 dose of study drug in either the Induction Study (Cohorts A and B) or the Maintenance Study. All-Cause Mortality: All Randomized Analysis Set included all participants who were randomized on Day 1 into each corresponding study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Induction Study (Cohort A): Filgotinib 200 mg</title>
          <description>Participants in Cohort A (biologic-naive) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Induction Study (Cohort A): Filgotinib 100 mg</title>
          <description>Participants in Cohort A (biologic-naive) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Induction Study (Cohort A): Placebo</title>
          <description>Participants in Cohort A (biologic-naive) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Induction Study (Cohort B): Filgotinib 200 mg</title>
          <description>Participants in Cohort B (biologic-experienced) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Induction Study (Cohort B): Filgotinib 100 mg</title>
          <description>Participants in Cohort B (biologic-experienced) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Induction Study (Cohort B): Placebo</title>
          <description>Participants in Cohort B (biologic-experienced) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg</title>
          <description>Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for an additional 47 weeks (up to Week 58).</description>
        </group>
        <group group_id="E8">
          <title>Maintenance Study: Placebo From Induction Filgotinib 200 mg</title>
          <description>Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).</description>
        </group>
        <group group_id="E9">
          <title>Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg</title>
          <description>Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for an additional 47 weeks (up to Week 58).</description>
        </group>
        <group group_id="E10">
          <title>Maintenance Study: Placebo From Induction Filgotinib 100 mg</title>
          <description>Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were rerandomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).</description>
        </group>
        <group group_id="E11">
          <title>Maintenance Study: Placebo From Induction Placebo</title>
          <description>Participants in the Placebo arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Appendiceal mucocoele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Dental cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Large intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Supernumerary teeth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Type I hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Procedural intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Haemorrhagic infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="83" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="77" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="55" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="67" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="33" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="53" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="33" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="26" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="18" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="16" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="10" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="277"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="262"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="285"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="142"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="202"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="179"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="91"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:&#xD;
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or&#xD;
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gilead Clinical Study Information Center</name_or_title>
      <organization>Gilead Sciences</organization>
      <phone>1-833-445-3230 (GILEAD-0)</phone>
      <email>GileadClinicalTrials@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

